Connection

David Mahvi to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications David Mahvi has written about Drug Administration Schedule.
David Mahvi
Connection Strength
0.023
Drug Administration Schedule
  1. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
    View in: PubMed
    Score: 0.014
  2. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997 Dec 03; 89(23):1789-96.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.